Drugs / House dust mite allergen extract
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00574223 | Nov 2007 → Mar 2009 | perennial allergic rhinitis | Cytos Biotechnology AG | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04851860 | Apr → Oct 2021 | allergic rhinitis | Zagazig University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00574704 Comparator | Sep 2006 → Mar 2008 | house allergic alveolitis, perennial allergic rhinitis | Cytos Biotechnology AG | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | House Dust Mite allergen extract | “received House Dust Mite allergen extract for sublingual immunotherapy or placebo” PMID 27329923 ↗ Apr 2016 |
| Route | Subcutaneous | “subcutaneous injections at 8 visits” NCT00574223 ↗ |